Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience. (1st January 2020)

• Record Type: Journal Article
• Authors: Marshall, A.D.; Grebely, J.; Dore, G.J.; Treloar, C.
• Is Part Of: Drug and alcohol dependence. Volume 206(2020)
• Publication Date: 2020-01-01
• Subjects: HCV -- DAA -- General practitioner -- Specialist -- DAA prescribing; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2019.107705
• Languages: English
• ISSNs: 0376-8716

Abstract

Highlights: Overall, participants found engagement in hepatitis C care a rewarding experience. Practitioners require further hepatitis C testing and liver disease staging support. Participants were unsure how to galvanise more practitioners into hepatitis C care. Abstract: Background: Since the advent of interferon-free, direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection, prescriber restrictions have been removed worldwide, permitting HCV management outside of hospital-based clinics. To date, there is limited knowledge of the practitioner experience with DAA treatments, particularly among those new to HCV care. The aim of this qualitative study was to investigate barriers and facilitators for HCV management among general practitioners (GPs) who prescribe opioid agonist therapy (OAT) and drug and alcohol specialists. Methods: In-depth, semi-structured telephone interviews were conducted between September 2018 and April 2019. Practitioners from across Australia were purposively sampled and questioned on barriers and facilitators to HCV management in their clinic(s). Data were coded and analysed with iterative categorisation and thematical analysis. Results: Thirty practitioners were interviewed. Participants expressed professional fulfillment in managing HCV care and many benefited from specialist mentorship. Most participants expressed frustration with ongoing implementation barriers, notably, a lack of onsite phlebotomy services and liver disease staging equipment. Poor venous access among persons who inject drugs was elucidated as a major barrier to treatment initiation. Some participants did not receive clinic manager support to engage in HCV care. Conclusion: To achieve HCV targets set by WHO by 2030, practitioners require additional implementation support. As HCV testing remains a barrier to linkage to care, practitioners should be kept well-informed of diagnostic developments. Findings also underscore the importance of initial specialist mentorship with further evidence needed for practitioners based in rural regions.